|
**Overview**: Cancer 3 Gene NGS Panel**Introduction**: The Cancer 3 Gene NGS Panel is a diagnostic tool designed to screen for selected cancer mutations using FFPE tissue samples. In India, focused NGS panels target key drivers (e.g., EGFR, KRAS, BRAF) in common cancers (lung, colorectal), where mutations guide targeted therapy (e.g., EGFR TKIs in 20-40 percent of non-small cell lung cancer). High burden of advanced cancers with under-testing of actionable mutations in rural/low-SES patients, limited NGS access, delayed precision therapy. Per molecular pathology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs NGS for 3-gene mutation analysis over 1-2 days with high sensitivity/specificity, valuable for cost-effective targeted screening. This diagnostic falls under genetic cancer screening and targets tumor tissue from specific cancers, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise treatment and improving outcomes. Its FFPE-based approach ensures reliable detection.**Other Names**: Cancer 3 Gene Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: Focused panels for affordability; in India, growing in oncology centers.**Purpose**: The test screens for 1 parameter (3 cancer gene mutation analysis) to guide cancer assessment, identify actionable mutations, inform targeted therapy.**Test Parameters**: 1. 3 Cancer Gene Mutation Analysis.**Pretest Condition**: No fasting required; patients should have confirmed cancer diagnosis with FFPE tissue available.**Specimen**: FFPE tissue block (0.5-2 cm³), transported within specified times to maintain sample viability.Sample Stability: Indefinite when properly stored (paraffin-embedded blocks stable long-term).**Medical History**: Patients should provide details on cancer type, stage, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated mutations including poor response, benefits of profiling, and minimal discomfort (tissue already collected).**Procedural Considerations**: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Poor tissue quality, low tumor content, or delays can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Actionable mutations indicate targeted therapy eligibility, necessitating specialist input. No mutations may require follow-up.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: IHC or broader NGS for confirmation.**Test Limitations**: Limited to 3 genes; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, NGS Studies India 2023. |
